Pressure pulsations enhance penetration index in COPD

Area of Science:

• Pulmonary Medicine
• Medical Devices
• Respiratory Therapy

Background:

• Chronic Obstructive Pulmonary Disease (COPD) management relies on effective inhaled medication delivery.
• Current nebulizer technologies may have limitations in reaching peripheral lung regions.
• Novel devices are needed to optimize aerosol deposition in patients with COPD.

Purpose of the Study:

• To evaluate the impact of a novel pressure pulsation device (Pulsehaler™) on inhaled aerosol deposition patterns in COPD patients.
• To compare the efficacy of Pulsehaler™ combined with a jet nebulizer (PH + NEB) versus a standard jet nebulizer (NEB) alone.
• To assess the effects on lung function, patient-reported outcomes, and aerosol distribution.

Main Methods:

• Fifteen COPD patients underwent spirometry and SPECT-CT lung scans.
• Albuterol aerosol was administered using a standard jet nebulizer (NEB) and a combined Pulsehaler™/jet nebulizer (PH + NEB).
• Aerosol deposition was quantified using SPECT-CT, analyzing total counts and peripheral-to-central ratios (Penetration Index, PI).

Main Results:

• The PH + NEB group showed significant improvements in FEV1, FVC, FEF25-75, and Borg scores compared to baseline and NEB alone.
• While total lung deposition was lower with PH + NEB, the Penetration Index (PI) was significantly higher (3.08 times greater).
• FEF25-75 and FEF75 showed significant improvements between the PH + NEB and NEB treatments.

Conclusions:

• The Pulsehaler™ device, when combined with a jet nebulizer, enhances aerosol penetration into the peripheral airways of COPD patients.
• Pressure pulsations may improve small airway patency, facilitating better drug delivery.
• Further research into pressure pulsation technology is warranted for optimizing inhaled therapy in respiratory diseases.